OncoVista Innovative Therapies Inc
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatmen… Read more
OncoVista Innovative Therapies Inc (OVIT) - Total Liabilities
Latest total liabilities as of September 2015: $6.65 Million USD
Based on the latest financial reports, OncoVista Innovative Therapies Inc (OVIT) has total liabilities worth $6.65 Million USD as of September 2015.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OncoVista Innovative Therapies Inc - Total Liabilities Trend (2000–2014)
This chart illustrates how OncoVista Innovative Therapies Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
OncoVista Innovative Therapies Inc Competitors by Total Liabilities
The table below lists competitors of OncoVista Innovative Therapies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crumbs Bake Shop Inc
PINK:CRMBQ
|
USA | $21.00 Million |
|
Bourque Indts Inc
PINK:BORK
|
USA | $1.75 Million |
|
Green Mountain Devel
PINK:GMND
|
USA | $2.70 Million |
|
Everlert Inc
PINK:EVLI
|
USA | $1.39 Million |
|
GeckoSystems International Corp
PINK:GOSY
|
USA | $318.33K |
|
Resgreen Group International Inc
PINK:RGGI
|
USA | $7.09 Million |
|
Health-Chem Corporation
PINK:HCLC
|
USA | $21.97 Million |
|
Technology Solutions Co
PINK:TSCC
|
USA | $1.27 Million |
Liability Composition Analysis (2000–2014)
This chart breaks down OncoVista Innovative Therapies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 108.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OncoVista Innovative Therapies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OncoVista Innovative Therapies Inc (2000–2014)
The table below shows the annual total liabilities of OncoVista Innovative Therapies Inc from 2000 to 2014.
| Year | Total Liabilities | Change |
|---|---|---|
| 2014-12-31 | $5.68 Million | +76.48% |
| 2013-12-31 | $3.22 Million | +42.65% |
| 2012-12-31 | $2.25 Million | -2.51% |
| 2011-12-31 | $2.31 Million | +22.11% |
| 2010-12-31 | $1.89 Million | -83.76% |
| 2009-12-31 | $11.66 Million | +31.00% |
| 2008-12-31 | $8.90 Million | -0.47% |
| 2007-12-31 | $8.94 Million | +381.29% |
| 2006-12-31 | $1.86 Million | +12.44% |
| 2005-12-31 | $1.65 Million | +21.59% |
| 2004-12-31 | $1.36 Million | +26.89% |
| 2003-12-31 | $1.07 Million | +51.70% |
| 2002-12-31 | $706.00K | +771.60% |
| 2001-12-31 | $81.00K | +37.29% |
| 2000-12-31 | $59.00K | -- |